FDA Approves Sanofi and Regeneron's Dupixent as First Treatment for AFRS

Key Facts

The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as the first and only treatment for Allergic Fungal Rhinosinusitis (AFRS). Developed by Sanofi and Regeneron Pharmaceuticals, the approval covers adults and children aged 6 years and older with a history of sino-nasal surgery. This milestone marks the ninth distinct indication for Dupixent in the U.S. within the category of type 2 inflammatory conditions. Clinical Phase 3 trials demonstrated that the drug significantly reduced nasal symptoms and decreased the reliance on systemic corticosteroids or further surgeries. The expansion into this new, previously untreated indication is expected to bolster the market position of the multi-billion dollar blockbuster drug. Investors view this development as a positive driver for both Sanofi and Regeneron's long-term revenue growth in the biotechnology sector.